- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-269/13 P: Judgment of the Court (Sixth Chamber) of 10 April 2014 — Acino AG v European Commission (Appeal — Medicinal products for human use — Suspension of the marketing and the withdrawal of certain consignments of medicinal products containing the active ingredient Clopidogrel — Variation of marketing authorisations — Prohibition on marketing — Regulation (EC) No 726/2004 and Directive 2001/83/EC — Precautionary principle — Proportionality — Obligation to state reasons)
ECLI:EU:UNKNOWN:62013CA0269
62013CA0269
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 175/14
(Case C-269/13 P) (<span class="super">1</span>)
((Appeal - Medicinal products for human use - Suspension of the marketing and the withdrawal of certain consignments of medicinal products containing the active ingredient Clopidogrel - Variation of marketing authorisations - Prohibition on marketing - Regulation (EC) No 726/2004 and Directive 2001/83/EC - Precautionary principle - Proportionality - Obligation to state reasons))
2014/C 175/16
Language of the case: German
Parties
Appellant: Acino AG (represented by: R. Buchner and E. Burk, Rechtsanwälte)
Other party to the proceedings: European Commission (represented by: M. Šimerdová and B.-R. Killmann, acting as Agents)
Re:
Appeal against the judgment of the General Court (Seventh Chamber) of 7 March 2013 in Case T-539/10 Acino v Commission, in so far as that Court dismissed an application for annulment of Commission Decisions C (2010) 2203, C (2010) 2205, C (2010) 2210 and C (2010) 2218 of 29 March 2010 and Commission Decisions C (2010) 6430, C (2010) 6432, C (2010) 6434 and C (2010) 6435 of 16 September 2010, relating to the suspension of the marketing of medicinal products for human use containing the active ingredient Clopidogrel manufactured at a certain site, the withdrawal of consignments of those medicinal products from the market, the variation of the marketing authorisations and the prohibition on marketing those medicinal products — Precautionary principle — Proportionality — Obligation to state reasons
Operative part of the judgment
The Court:
1.Dismisses the appeal.
2.Orders Acino AG to pay the costs.
(<span class="super">1</span>) OJ C 215, 27.07.2013.